Since no comprehensive cure has been found for multiple myeloma or blood cancer the focus then shifts to managing the disease effectively to prolong the multiple myeloma life expectancy of patients suffering from this dreaded disease. However there is no standardized treatment for controlling myeloma in patients and each one of them has to follow a treatment regime that is personalized to their needs. But past records show that traditional treatments with track records have proven to be effective in controlling the disease.
When treating a patient for multiple myeloma several factors have to be taken into account. The factors to consider are the general health condition of the patient, other medical issues if any, effectiveness of the treatment in controlling the disease, and how the patient responded to the therapies earlier. Several options should be tried and tested in diagnosis and deciding its treatment because numerous tests are available.
Patients suffering from multiple myeloma are advised participation in clinical trials so that they are given advanced therapies. These trials are intended to be as effective as the conventionally tried treatments particularly during phase 2 and phase 3. Scope of disease management options depends on the classification of the patient’s disease status and classification.
How you classify the disease?
Patients with multiple myeloma are divided into two classifications: Active disease or Inactive disease. The later is without any symptoms and does not necessitate immediate treatment. It also does not show any tissue or organ related impairment caused by myeloma. Inactive myeloma also divides into subclasses namely monoclonal gammonpathy of undetermined significance (MGUS), indolent myeloma (IMM) and Smoldering Myeloma (SMM).
Treatment is required for active or symptomatic myeloma needs treatment. Patients suffering from the disease in stage 2 or stage 3 come into this category. The therapy options differ from those who have already gone through the treatment process and the one who have not received any treatment. The disease status of the patients is entirely taken into consideration before commencing treatment. There are the newly diagnosed patients with myeloma that is yet to be treated.
All these are to be taken into account before starting an individualized treatment process for the myeloma affected patient. The newly approved drugs that have come up in recent months have greatly amplified the hopes of patients in increasing the multiple myeloma life expectancy. However there is no wonder drug seems to be appearing on the horizon in the near future hence the patients with blood cancer will have to rely on the Myeloma Management to prolong their life span.